NCT04883242 2026-03-13
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT04270175 2026-02-27
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT02718833 2026-01-22
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04802161 2025-12-19
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04850599 2025-12-18
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT04126200 2025-11-06
DREAMM5
GlaxoSmithKline
Phase 2 Active not recruiting
NCT05911321 2025-10-20
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04302324 2025-10-01
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT04124497 2025-08-08
DPd
Fondazione EMN Italy Onlus
Phase 2 Active not recruiting
NCT02719613 2025-06-05
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT05669989 2025-01-23
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Sanofi
Phase 2 Active not recruiting
NCT02406222 2024-12-05
MUKseven
University of Leeds
Phase 2 Active not recruiting